编号：2024-006 证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 投 资者关系 活动类别 □ 特定对象调研 □ 分析师会议 □ 媒体采访 □ 业绩说明会 □ 新闻发布会 □ 路演活动 | --- | --- | |------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | 现场参观 □ 其他（线上会议） | | 参与人员 | 珠海上市公司协会、华泰证券、广州私募基金协会、汇聚投资、玄甲基金、 宸 泽基金、太朴持信 ...

公司快报 2024 年 10 月 25 日 健帆生物(300529.SZ) 24Q3 延续高增长，经营韧性显现 事件：公司发布三季报，前三季度公司业绩实现快速增长。 24Q1-3，公司实现收入 21.96 亿元，同比增长 47.76%；归母净利润 7.92 亿元，同比增长 86.86%。24Q3，公司实现收入 7 亿元，同比增 长 47.74%；归母净利润 2.39 亿元，同比增长 63.62%。 公司毛利率、净利率同比均有明显提升，得益于高端产品放量 和收入基数提升。 24Q1-3，公司毛利率 81.31%，同比提升 0.65pct，核心原因为 KHA、 PHA 等高价产品为今年推广重点，对冲掉了 HA130 降价影响；净利率 35.93%，同比提升 7.64pct，主要系 23 年公司由于去库存影响报表 端确认收入较少，而维持终端纯销所需的费用并未一同下降导致费用 率虚高。24Q3，公司实现毛利率 82.97%、净利率 34.01%，环比基本 保持稳定。 公司库存处于良性水平，后续增长动力强劲。 经历 22 年下半年至 23 年的调整，公司在 24 年初已达到低库存状态。 关于 24Q3 收入端未出现环比 ...

证券研究报告 健帆生物 (300529 CH) 3Q24 公司业绩延续快速增长势头 华泰研究 季报点评 2024 年 10 月 19 日│中国内地 医疗器械 健帆生物发布 24 年三季报：1-3Q24 实现收入 21.96 亿元（yoy+47.8%）、 归母净利润 7.92 亿元（yoy+86.9%），其中 3Q24 实现收入 7.00 亿元 （yoy+47.7%）、归母净利润 2.39 亿元（yoy+63.6%）。公司血液灌流器、 吸附器等核心产品销售放量喜人，驱动整体业绩快速增长。考虑血液灌流疗 法渗透率持续提升、公司产品学术推广进一步强化，叠加前期内部营销改革 成效陆续显现，我们看好公司 24 全年业绩保持快速增长势头。维持买入。 看好公司核心产品 24 年收入保持快速增长 我们推测公司血液灌流器等核心产品 1-3Q24 整体收入同比实现快速增长。 公司核心产品院内认可度高、循证证据丰富且新品推广进展顺利，包括：1） 院内认可高：截至 1H24，公司肾科、肝科产品医院覆盖量分别超 6000/2000 家；2）循证证据多：截至 1H24，公司肾科 KHA 系列产品已获国内相关专 家共识推荐，肝科 DPMA ...

Revenue and Profit Growth - Revenue for the third quarter reached 700,065,714.12 yuan, a year-on-year increase of 47.74%[2] - Net profit attributable to shareholders of the listed company was 239,128,282.41 yuan, up 63.62% compared to the same period last year[2] - Revenue increased by 47.76% to 2,195,690,243.92 yuan, driven by rapid growth in sales of perfusion and adsorption products[7] - Net profit surged by 87.63% to 788,826,841.30 yuan, primarily due to increased sales revenue and a decrease in period expense ratio[8] - Operating revenue for the period reached 2,195,690,243.92 yuan, compared to 1,485,982,086.00 yuan in the same period last year[22] - Net profit attributable to the parent company's owners rose to 2,485,766,350.81 yuan, up from 2,003,918,783.75 yuan at the beginning of the period[21] - Net profit attributable to parent company shareholders reached RMB 791.63 million, a significant increase from RMB 423.66 million in the same period last year[23] - The company's total comprehensive income for the period was RMB 788.83 million, up from RMB 420.44 million in the previous year[24] Asset and Liability Changes - Total assets as of the end of the reporting period were 5,593,125,792.01 yuan, an increase of 0.90% from the end of the previous year[2] - Total assets increased to 5,593,125,792.01 yuan, up from 5,543,301,641.00 yuan at the beginning of the period[21] - Total liabilities decreased to 2,299,898,618.97 yuan, down from 2,390,427,115.63 yuan at the beginning of the period[20] - Total equity attributable to the parent company's owners increased to 3,289,267,081.77 yuan, up from 3,147,475,025.76 yuan at the beginning of the period[21] Cash Flow and Financial Activities - Cash flow from operating activities increased by 47.72% to 871,604,805.56 yuan, driven by higher sales revenue and improved collection[9] - Investment activities resulted in a net cash outflow of 2,177,751,665.93 yuan, mainly due to the purchase of financial products[10] - Financing activities led to a net cash outflow of 727,689,551.18 yuan, primarily due to reduced bank borrowings and increased share repurchase payments[10] - Cash flow from operating activities increased to RMB 871.60 million, up from RMB 590.04 million in the prior year[26] - Investment activities resulted in a net cash outflow of RMB 2.18 billion, primarily due to investment payments of RMB 3.57 billion[26][27] - Financing activities generated a net cash outflow of RMB 727.69 million, with debt repayments totaling RMB 364.16 million[27] Financial Position and Cash Equivalents - The company's monetary funds decreased by 74.35% to 720,879,803.21 yuan, mainly due to the purchase of financial products and payment of share repurchases and dividends[5] - Cash and cash equivalents decreased by 73.71% to 706,919,138.82 yuan, mainly due to the purchase of financial products and share repurchase payments[10] - Cash and cash equivalents stood at 720,879,803.21 yuan, a significant drop from 2,810,294,219.25 yuan at the beginning of the period[18] - The company's cash and cash equivalents at the end of the period stood at RMB 706.92 million, a decrease from RMB 2.69 billion at the beginning of the period[27] Shareholder and Equity Information - The total number of ordinary shareholders at the end of the reporting period is 47,817[11] - Dong Fan holds 44.47% of the shares, totaling 355,131,867 shares[11] - Tang Xianmin holds 2.67% of the shares, totaling 21,336,425 shares[11] - China Bank Co., Ltd. - Huabao CSI Medical ETF holds 2.04% of the shares, totaling 16,261,281 shares[11] - Hong Kong Securities Clearing Company Ltd. holds 1.59% of the shares, totaling 12,689,098 shares[11] - Industrial and Commercial Bank of China Co., Ltd. - E Fund ChiNext ETF holds 1.50% of the shares, totaling 11,998,489 shares[11] - Agricultural Bank of China Co., Ltd. - CSI 500 ETF holds 1.12% of the shares, totaling 8,958,300 shares[11] - Guo Xuerui holds 1.01% of the shares, totaling 8,040,792 shares[11] - Jiang Huanxin holds 1.00% of the shares, totaling 8,000,882 shares[11] - China Bank Co., Ltd. - China Merchants Guozheng Biopharmaceutical Index Fund holds 0.98% of the shares, totaling 7,791,386 shares[11] Expenses and Costs - Operating costs rose by 42.80% to 410,333,473.21 yuan due to increased sales of perfusion and adsorption products[7] - Financial expenses surged by 185.67% to 49,843,991.71 yuan due to a decrease in deposit ratio and increased interest expenses on convertible bonds[7] - Income tax expenses increased by 111.33% to 165,792,667.72 yuan, driven by higher sales revenue and profits[8] - Research and development expenses amounted to 174,715,744.33 yuan, slightly down from 176,357,010.23 yuan in the same period last year[22] - Interest expenses increased to RMB 47.95 million, up from RMB 40.29 million in the previous year[23] Other Financial Metrics - Transactional financial assets increased to 1,993,010,954.97 yuan, primarily due to the purchase of financial products[5] - Accounts receivable financing surged by 1576.55% to 106,616,453.05 yuan, driven by an increase in bank acceptance bills held at the end of the period[5] - Prepayments rose by 143.63% to 28,189,361.94 yuan, mainly due to increased prepayments for raw material purchases[5] - Construction in progress increased by 52.72% to 186,975,903.32 yuan, reflecting higher investments in production equipment and factory construction[5] - Taxes payable surged by 119.17% to 125,821,283.55 yuan, driven by growth in sales revenue and profits[6] - Long-term loans decreased by 31.70% to 276,565,114.40 yuan, partly due to early repayment of some bank loans and reclassification of maturing loans[6] - Government subsidies increased by 49.84% to 52,078,282.13 yuan compared to the same period last year[7] - Trade receivables increased to 92,523,595.64 yuan, up from 74,850,201.41 yuan at the beginning of the period[18] - Inventory decreased to 312,560,202.84 yuan, down from 384,996,423.31 yuan at the beginning of the period[18] - Fixed assets stood at 1,617,425,679.54 yuan, down from 1,633,717,142.19 yuan at the beginning of the period[19] - Basic earnings per share (EPS) for the current period was RMB 0.99, compared to RMB 0.53 in the previous year[24] - Sales revenue from goods and services provided reached RMB 2.31 billion, a rise from RMB 1.78 billion in the previous year[25] - Other income rose to RMB 52.08 million, compared to RMB 34.76 million in the same period last year[23] - The company's third quarter report was not audited[28]

证券代码：300529 证券简称：健帆生物 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 投资者关系活动记录表 | --- | --- | --- | --- | --- | --- | |-----------------------|--------------------------------------------------------------|-------|-----------------------------------------------------------------------------------------------------------|--------------------------|---------------------------| | | \n□ 特定对象调研 | | □ 分析师会议 | 编号： | 2024-005 | | 投资者关系 | □ 媒体采访 √ | | 业绩说明会 | | | | 活动类别 | □ 新闻发布会 | | □ 路演活动 | | | | | □ 现场参观 □ | | 其他（线上会议） | | ...

证券代码：300529 证券简称：健帆生物 公告编号：2024-075 债券代码：123117 债券简称：健帆转债 健帆生物科技集团股份有限公司 关于参加广东辖区 2024 年投资者网上集体接待日活动的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 为进一步加强与投资者的交流沟通，健帆生物科技集团股份有限公司（以下 简称"公司"）将参加由广东证监局、广东上市公司协会联合举办的"坚定信心 携 手共进 助力上市公司提升投资价值——2024 广东辖区上市公司投资者关系管 理月活动投资者集体接待日"，现将相关事项公告如下： 本次活动将采用网络远程的方式举行，投资者可登录"全景路演"网站 （http://rs.p5w.net）参与本次互动交流，活动时间为 2024 年 9 月 12 日（星期四） 15:30 ~16:30。 届时公司董事长兼总经理董凡先生、董事兼财务总监廖雪云女士、董事会秘 书黄聪女士将通过网络在线方式，与投资者就公司治理、经营情况及发展战略等 投资者关心的问题，与投资者进行沟通与交流，欢迎广大投资者积极参与。 特此公告。 健帆生物科技集团股份有限 ...

本报告仅供 Choice 东方财富 使用，请勿传阅。 证券研究报告 医疗器械 投资评级 买入-A 维持评级 6 个月目标价 40.1 元 股价 (2024-08-12) 26.38 元 交易数据 总市值(百万元) 21,300.57 流通市值(百万元) 13,752.80 总股本(百万股) 807.45 流通股本(百万股) 521.33 12 个月价格区间 16.6/30.47 元 升幅% 1M 3M 12M 相对收益 -4.2 -0.7 29.1 绝对收益 -8.5 -10.0 14.7 马帅 分析师 相关报告 健帆生物 24H1 业绩高增 长，基本面持续回暖 2024-07-15 24Q1 业绩大幅改善，基本面 反转拐点已至 2024-04-26 健帆生物深度推荐：荆棘载 途终有尽，繁花前路仍可期 2024-03-17 发布"质量回报双提升"方 2024-03-07 案，血液灌流国产龙头推进 全球高质量发展 公司快报 2024 年 08 月 16 日 健帆生物(300529.SZ) 24Q2 延续高增长，公司重回快车道 事件：公司发布 2024 年中报。 24H1，公司实现收入 14.96 亿元，同比增长 ...

上 市 公 司 证 券 研 究 报 告 医药生物 2024 年 08 月 13 日 健帆生物 (300529) ——2024H1 业绩符合预期，公司重归高增通道 | --- | --- | |------------------------------------|-------------------------------| | 市场数据： | 2024 年 08 月 13 日 | | 收盘价（元） | 26.48 | | 一年内最高 / 最低（元） | 30.65/15.88 | | 市净率 | 7.3 | | 息率（分红/股价） | 1.51 | | 流通 A 股市值（百万元） | 13,805 | | 上证指数/深证成指 | 2,867.95/8,409.22 | | 注："息率"以最近一年已公布分红计算 | | | --- | --- | |-------------------------------|------------------------| | | | | 基础数据 : | 年 06 月 30 日 | | | | | 每股净资产（元） | 3.62 | | | | | 资产负债率 % ...

Equity Research Report Jafron Biomedical (300529 CH) Earnings Grew Strongly in 2024 Huatai ResearchInterim Results Review 13 August 2024 | China (Mainland)Medical Devices Earnings growth continued to pace up in 2Q24; maintain BUY Jafron Biomedical (Jafron) registered 1H24 revenue/attributable net profit (NP) of RMB1,496/553mn (up 47.8/99.1% yoy) and 2Q24 revenue/attributable NP of RMB751/268mn (up 70.9/230.6% yoy), which further picked up from the growth rates in 1Q24 (revenue/attributable NP: up 30/44.9% y ...

[ T able_StockInfo] 2024 年 08 月 08 日 证券研究报告•2024 年半年报点评 当前价：27.15 元 健帆生物（300529）医药生物 目标价：——元（6 个月） 41543 产品恢复高增长，盈利能力改善 [Table_Summary 事件：公司发布] 2024年半年报，实现营业收入 14.96亿元，同比增长 47.8%； 实现归属于母公司股东净利润 5.5 亿元，同比增长 99.1%；实现扣非后归母净 利润 5.3 亿元，同比增长 100%。 渠道库存改善，业绩恢复增长。分季度看，公司 2024Q1/Q2实现营业收入 7.4/7.5 亿元（+30%/+70.9%），实现归母净利润 2.9/2.7亿元（+44.9%/+230.6%）。24H1 公司外部政策环境得到一定改善。肾病、肝病、危急重症领域业务发展较好。 从盈利能力来看，公司以降本增效原则开展各类经营活动，盈利能力提升明显。 2024 年 H1毛利率为 80.5%（-0.01pp）。销售费用率为 22.8%（-9.2pp），管理 费用率为 5.7%（-1.545pp），研发费用率为 7.5%（-3.78pp），销售费用 ...